Business
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond
About this update from Indivior Pharmaceuticals, Inc.
[{"type":"text","content":"BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioidsRICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE® (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdose emergencies. OPVEE is the first and only nasal rescue medicine specifically indicated for synthetic opioids like fentanyl.\n\n \n \n \n \n \n \n\n \nOpioid overdose deaths continue to claim lives in the U.S. with over 76,922 fatal overdoses in the one-year period ending in January 2024.1 Access to effective opioid overdose reversal treatments is essential to reducing preventable deaths and helping communities against the evolving threat landscape. With its first order of OPVEE, BARDA will be able to supplement local supplies of emergency opioid overdose medications for emergency rooms, ambulances, and other sites in the United States if medical countermeasure shortages occurred during an emergency response.\n\"Providing communities with effective tools to address the fentanyl crisis is essential,\" said Richard Simkin, Chief Commercial Officer and Head of Government Affairs, Indivior. \"This order of OPVEE has the potential to support the nation's preparedness against potential biothreats and response efforts to reduce overdose deaths from fentanyl and other synthetic opioid poisonings.\"\nBARDA will use $8.7 million in Project BioShield designated funding for the initial procurement. The first option was exercised under the agreement with Indivior that was announced in December 2023. BARDA has the option to purchase additional OPVEE annually under Indivior vendor managed inventory over the next nine years.\nOPVEE would be used in the prehospital setting (first responder/EMS) in accidental or intentional mass casualty situations.2,3 The need for this product is pressing given the increase in fentanyl overdoses in the US.\nThis project has ...